Transplant-Ineligible Myeloma: Adding Daratumumab to VMP Increases Survival

Adding daratumumab to bortezomib/melphalan/prednisone (VMP) increases overall survival in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), according to results of the phase 3 ALCYONE trial to be presented in December at the American Society of Hematology (ASH) Annual Meeting and Exposition. Patients who are ineligible for autologous stem cell transplantation comprise approximately half of NDMM patients, and the combination of bortezomib, a proteasome inhibitor, with m...
Continue reading

Acalabrutinib, Alone or in Combination, Improves Progression-Free Survival in CLL

​ In previously untreated chronic lymphocytic leukemia (CLL), acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival either as monotherapy or in combination with obinutuzumab (Gazyva®, Genentech), according to interim results of the phase 3 ELEVATE-TN trial to be presented at the American Society of Hematology (ASH) Annual Meeting. Acalabrutinib, a highly selective, covalent irreversible Bruton tyrosine kinase inhibitor, is currently FDA approved for the treatment of relapsed...
Continue reading

Gregg Semenza, MD, PhD: The Role of HIF-1 and HIF-2 in Cancer

Gregg L. Semenza, MD, PhD, was recently awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in isolating hypoxia inducible factor (HIF) 1, which controls genes that are involved in cells' adaptation to low oxygen levels, with implications for cancer, ischemia, and chronic lung disease. In this interview with i3 Health, Dr. Semenza discusses the involvement of HIF-1 and HIF-2 in cancer and shares insights on the progress that is being made in developing HIF-1 and HIF-2 i...
Continue reading

Post-Immunotherapy Axitinib for Patients With Renal Cell Carcinoma

For patients with metastatic renal cell carcinoma (RCC), checkpoint inhibitor therapy is the standard of care. However, if that doesn't work, vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors can be the next option, but there is no prospective data on the efficacy of these drugs for RCC in this setting. In an attempt to provide evidence for the effectiveness of VEGF-R tyrosine kinase inhibitors for RCC previously treated with immune checkpoint inhibitors, researcher...
Continue reading

JMJD6 Identified as a Neuroblastoma Tumorigenic Factor

Researchers have identified the JMJD6 gene as a critical factor for neuroblastoma tumorigenesis, indicating potential for a new targeted drug therapy treatment strategy. The most prevalent solid tumor in early childhood cancers, neuroblastoma comprises 15% of total childhood cancer deaths. Neuroblastoma is distinctive from adult cancers in that it is characterized by frequent chromosome copy number variations, and its most prominent features are gene deletion, amplification, or gain. While chrom...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.